DTTC Frequency for Childhood Apraxia of Speech
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores the optimal frequency of treatment sessions for children with childhood apraxia of speech (CAS), a condition affecting the ability to plan and produce speech sounds. Researchers aim to determine whether sessions twice a week for 12 weeks are more or less effective than sessions four times a week for 6 weeks. The trial seeks children diagnosed with CAS who speak English as their primary language. Children meeting these criteria and not currently receiving other speech treatments may be suitable candidates for this study. The treatment under investigation is called Dynamic Temporal and Tactile Cueing Treatment. As an unphased trial, this study provides a unique opportunity to enhance understanding of effective treatment scheduling for CAS.
Will I have to stop taking my current medications?
The trial information does not specify whether participants need to stop taking their current medications. However, it does mention that children cannot receive speech treatment elsewhere during the study.
What prior data suggests that Dynamic Temporal and Tactile Cueing Treatment is safe for children with Childhood Apraxia of Speech?
Research has shown that Dynamic Temporal and Tactile Cueing (DTTC) is safe for children with childhood apraxia of speech (CAS). Past studies have used this treatment successfully without major safety issues. Reports indicate that children tolerate DTTC well. It improves speech through a hands-on method where children repeat words and phrases to practice and enhance their speaking skills.
No evidence links DTTC to negative effects. Studies consistently find it effective and safe for helping children with CAS improve their speech. Notably, DTTC is a therapy-based treatment, not a medication, which reduces the risks often associated with drug treatments. Overall, DTTC is considered a safe option for addressing speech difficulties in children with CAS.12345Why are researchers excited about this trial?
Researchers are excited about the Dynamic Temporal and Tactile Cueing (DTTC) Treatment for Childhood Apraxia of Speech because it explores how the frequency of therapy sessions impacts effectiveness. Unlike traditional speech therapy, which often follows a more rigid schedule, this approach tests both low and high-frequency session models to see which yields better results. By comparing two different treatment frequencies, researchers aim to discover the optimal way to help children improve their speech skills more efficiently. This could lead to more personalized and effective treatment plans for kids struggling with this challenging condition.
What evidence suggests that this trial's treatments could be effective for childhood apraxia of speech?
Research shows that Dynamic Temporal and Tactile Cueing (DTTC) is an effective treatment for childhood apraxia of speech (CAS). Studies have found that DTTC, which focuses on improving movement, helps children with CAS speak more clearly. This treatment uses timing and touch to guide children in saying words correctly. Children who received DTTC demonstrated significant improvements in their speech. This trial will compare different frequencies of DTTC sessions: one group will receive treatment twice a week for 12 weeks, while another group will receive treatment four times a week for 6 weeks. Although researchers are still determining the optimal session frequency, evidence strongly supports DTTC's effectiveness in helping children with CAS improve their speech.16789
Who Is on the Research Team?
Jenya Iuzzini-Seigel, PhD
Principal Investigator
Marquette University
Are You a Good Fit for This Trial?
This trial is for children aged between 2 years and 6 months to 7 years and 11 months with a confirmed diagnosis of Childhood Apraxia of Speech (CAS). They must speak English primarily, have no severe developmental disorders, uncorrected vision or hearing loss, significant speech treatment from other sources during the study, or cognitive scores below certain thresholds.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive DTTC treatment with varying dose frequencies: 4 times per week for 6 weeks or 2 times per week for 12 weeks
Follow-up
Participants are monitored for treatment gains and generalization of speech improvements
What Are the Treatments Tested in This Trial?
Interventions
- Dynamic Temporal and Tactile Cueing Treatment
Find a Clinic Near You
Who Is Running the Clinical Trial?
Marquette University
Lead Sponsor
New York University
Collaborator
Remarkable Speech and Movement
Collaborator
University of Vermont
Collaborator
Hofstra University
Collaborator
University of Sydney
Collaborator